Molecular Financial Statements From 2010 to 2024
| MLPH Stock | USD 0.0001 0.00 0.00% |
Check Molecular Pharmacology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Pharmacology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Molecular financial statements analysis is a perfect complement when working with Molecular Pharmacology Valuation or Volatility modules.
Molecular |
Molecular Pharmacology Company Current Valuation Analysis
Molecular Pharmacology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Molecular Pharmacology Current Valuation | 221.59 K |
Most of Molecular Pharmacology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Pharmacology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Molecular Pharmacology has a Current Valuation of 221.59 K. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Molecular Pharmacology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecular Pharmacology's current stock value. Our valuation model uses many indicators to compare Molecular Pharmacology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Pharmacology competition to find correlations between indicators driving Molecular Pharmacology's intrinsic value. More Info.Molecular Pharmacology is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Molecular Pharmacology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Molecular Pharmacology's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Molecular Pharmacology Financial Statements
Investors use fundamental indicators, such as Molecular Pharmacology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Molecular Pharmacology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. Molecular Pharmacology Limited is a subsidiary of PharmaNet Group Limited. Molecular Pharmacology is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.